Bio-Rad Laboratories
(BIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 407,272 | 383,824 | 328,894 | 321,584 | 291,663 |
| Marketable Securities | 361,221 | 376,714 | 392,123 | 395,828 | 386,972 |
| Receivables | 430,361 | 464,847 | 419,708 | 392,842 | 373,443 |
| Inventories | 612,217 | 594,804 | 601,571 | 580,581 | 559,819 |
| Other current assets | 166,045 | 10,325 | 8,927 | 10,038 | 120,674 |
| TOTAL | $1,977,116 | $1,976,649 | $1,892,451 | $1,826,528 | $1,732,571 |
| Non-Current Assets | |||||
| PPE Net | 499,708 | 493,496 | 500,687 | 503,329 | 505,104 |
| Investments And Advances | 2,981,768 | 1,027,736 | 1,032,801 | 1,040,959 | 955,620 |
| Intangibles | 678,571 | 680,182 | 701,839 | 715,106 | 706,805 |
| Other Non-Current Assets | 77,749 | 94,949 | 57,950 | 57,537 | 52,669 |
| TOTAL | $4,237,796 | $2,296,363 | $2,293,277 | $2,316,931 | $2,220,198 |
| Total Assets | $6,214,912 | $4,273,012 | $4,185,728 | $4,143,459 | $3,952,769 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 369 | 420 | 452 | 505 | 466 |
| Accounts payable and accrued liabilities | 259,365 | 135,182 | 273,958 | 0 | 0 |
| Accrued Expenses | N/A | 171,632 | N/A | 277,566 | 231,485 |
| Other current liabilities | 154,087 | 127,288 | 161,063 | 143,731 | 142,511 |
| TOTAL | $456,198 | $502,696 | $466,456 | $455,110 | $407,504 |
| Non-Current Liabilities | |||||
| Long Term Debt | 434,678 | 434,581 | 434,475 | 434,386 | 434,289 |
| Deferred Revenues | N/A | 28,233 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 190,988 | 183,276 | 147,779 | 148,123 | 403,510 |
| TOTAL | $1,270,623 | $840,066 | $870,825 | $877,352 | $837,799 |
| Total Liabilities | $1,726,821 | $1,342,762 | $1,337,281 | $1,332,462 | $1,245,303 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,805 | 29,805 | 29,764 | 29,638 | 29,606 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 4,013,232 | 1,830,439 | 1,880,765 | 1,853,372 | 1,848,337 |
| Other shareholders' equity | 103,868 | 738,577 | 616,945 | 610,964 | 516,542 |
| TOTAL | $4,488,091 | $2,930,250 | $2,848,447 | $2,810,997 | $2,707,466 |
| Total Liabilities And Equity | $6,214,912 | $4,273,012 | $4,185,728 | $4,143,459 | $3,952,769 |